For Diagnosing and Treating Lupus Nephritis, Every Minute Counts

Authored by Aurinia Pharma U.S., Inc.


Once patients with systemic lupus erythematosus (SLE) have been diagnosed with lupus nephritis (LN), they may have already suffered irreparable kidney damage.1 Understanding the risks of LN and the actions to improve long-term kidney health is essential for better patient outcomes. When it comes to each untreated episode of LN, patients with SLE are losing more than time.2

Understanding the risks of LN

It is important to begin active surveillance for LN when patients are diagnosed with SLE. In fact, almost 35% of patients may have LN at the time of their SLE diagnosis.1 Even one LN episode can result in irreversible nephron loss.2 Further, ongoing episodes can lead to more severe kidney damage.2

Despite these risks, too few patients with suspected LN receive timely biopsies, which can heighten the risk of kidney failure and delay treatment.3,4 Slowing LN progression with early biopsy and prompt treatment is vital for your patients’ health.

Be proactive

Because time is imperative with LN, recent EULAR/ERA-EDTA guidelines have outlined more urgent recommendations for diagnosing and treating LN in patients with SLE.2,5,6 At the first sign of kidney involvement, patients should be referred for biopsy to avoid delays in treatment.6,7

The guidelines also recommend specific proteinuria treatment targets to achieve optimal results.6 Rapid reductions in proteinuria are associated with improved long-term patient outcomes.8 For your patients with SLE, be proactive with LN diagnosis and treatment.


Visit [] to learn more about the actions you can take to improve outcomes for your patients with LN.

At Aurinia Pharma U.S., Inc., our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease. Discover more about Aurinia at [link to].

[end matter]

ERA-EDTA=European Renal Association-European Dialysis and Transplant Association; EULAR=European League Against Rheumatism; GFR=glomerular filtration rate; LN=lupus nephritis; SLE=systemic lupus erythematosus.

References: 1. Izmirly PM, et al. Arthritis Rheum. 2017;69(10):2006-2017. 2. Anders HJ, et al. Nat Rev Dis Primers. 2020;6(1):7. 3. Aggarwal I, et al. Arthritis Care Res (Hoboken). 2020;72(7):888-896. 4. Faurschou M, et al. J Rheumatol. 2006;33(8):1563-1569. 5. Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745. 6. Fanouriakis A, et al. Ann Rheum Dis. 2020;79(6):713-723. 7. Hahn BH, et al. Arthritis Care Res (Hoboken). 2012;64(6):797-808. 8. Tamirou F, et al. Ann Rheum Dis. 2016;75(3):526-531.

Copyright ©2021, Aurinia Pharma U.S., Inc.

All rights reserved. (4/21) US-NA-2100077

Posted by
  • As a speaker at the first ad hoc meeting of rheumatology practice managers gathered in a single small room at its infancy a decade ago, I’m amazed to see how NORM has blossomed into a high energy organization of depth and professional meetings with parallel break-out symposia between plenary sessions. NORM has truly come of age. This is where the “business” of rheumatology gets learned. The ”guildmanship” for rheumatology practice management is now strong.- Paul H. Caldron, DO, FACP, FACR, MBA, Arizona Arthritis and Rheumatology Associates
  • In a time of demanding changes in the management of medical practices in the US, NORM has been a lifesaver to the community of Rheumatology practices.  NORM has allowed our practice to stay ahead of the many demands of CMS and others payors and has ensured that our practice remains cognizant of new issues that arise in HIPPA compliance, human resources and medical billing to name a few. Sending our Practice Manager to NORM's conferences has been cost-effective and beneficial to our practice because she returns to our office with an abundance of information that otherwise would have taken months to compile. Every Rheumatology practice that wishes to stay on top of emerging issues in practice management should consider sending a member of their staff to NORM's conference.- Michael S. Rosen M.D., Chester County Rheumatology PC
  • Thanks to all those wonderful people in the NORM Network who respond to emails, offering their advice, experience, time, and support ... I haven't even been a member a full year yet and I am amazed at the dedication of everyone who responds to helping via emails and the NORM Organization itself! I have barely had a chance to explore the resources and I have yet to really dive into requests for help still I am silently learning so much and do occasionally offer what I can! Thank you all!- Cheryl Piambino, Kenneth E. Bresky, DO

What We Offer

We’re adding value to practices across the nation by creating a thriving community of rheumatology managers and physicians.

Membership Benefits

Become a Member

Annual Conference

Conference Registration